Raymond James Financial Inc. Purchases Shares of 373,911 Enovis Co. (NYSE:ENOV)

Raymond James Financial Inc. purchased a new position in Enovis Co. (NYSE:ENOV - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 373,911 shares of the company's stock, valued at approximately $16,407,000. Raymond James Financial Inc. owned 0.66% of Enovis at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Aster Capital Management DIFC Ltd purchased a new position in shares of Enovis in the fourth quarter valued at $29,000. Quadrant Capital Group LLC grew its stake in Enovis by 53.0% in the 4th quarter. Quadrant Capital Group LLC now owns 690 shares of the company's stock valued at $30,000 after acquiring an additional 239 shares during the last quarter. UMB Bank n.a. increased its holdings in Enovis by 128.2% during the 4th quarter. UMB Bank n.a. now owns 778 shares of the company's stock valued at $34,000 after acquiring an additional 437 shares in the last quarter. Pinnacle Bancorp Inc. raised its position in Enovis by 54.5% during the fourth quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company's stock worth $37,000 after acquiring an additional 300 shares during the last quarter. Finally, FMR LLC lifted its holdings in shares of Enovis by 20.5% in the third quarter. FMR LLC now owns 2,840 shares of the company's stock valued at $122,000 after purchasing an additional 484 shares in the last quarter. 98.45% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Needham & Company LLC restated a "buy" rating and set a $64.00 price objective on shares of Enovis in a research report on Wednesday, April 9th.

Enovis Trading Down 0.5 %

NYSE:ENOV traded down $0.19 on Friday, reaching $34.93. The stock had a trading volume of 157,920 shares, compared to its average volume of 745,622. The company has a market cap of $2.00 billion, a price-to-earnings ratio of -15.95 and a beta of 1.86. Enovis Co. has a 12-month low of $29.32 and a 12-month high of $56.43. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. The firm's fifty day moving average is $36.70 and its two-hundred day moving average is $41.98.

Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.06. The business had revenue of $560.98 million for the quarter, compared to the consensus estimate of $555.14 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. Equities analysts expect that Enovis Co. will post 2.79 EPS for the current fiscal year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.